# Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer

Source: https://onco.cc/trials/nct06222879/  
OnCo record `nct06222879` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HRS-8080, Trastuzumab rezetecan, SHR-A2009 and Adebrelimab in advanced solid tumours, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.

## Summary

Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT06222879 by Shandong Suncadia Medicine Co., Ltd., with 350 participants planned, started 2024-02-20 and due to reach its primary completion in 2026-10-31. Interventions recorded: HRS-8080; SHR-A1811, HRS-8080; SHR-A2009 and SHR-A2009; SHR-1316.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06222879
- Phase: 1/2
- Setting: A Multi-center, Open-label Phase Ib/II Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer
- Sponsor: Shandong Suncadia Medicine Co., Ltd.
- Enrolled: 350

## Sources

- ClinicalTrials.gov NCT06222879: https://clinicaltrials.gov/study/NCT06222879

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [HRS-8080](https://onco.cc/drugs/hrs-8080/), [SHR-A2009](https://onco.cc/drugs/shr-a2009/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06222879.json